In August 2022, Myeloma New Zealand is hosting its 4th Myeloma Summit for medical professionals in Queenstown. Held in 2016,2018, 2020 and now again in 2022, the Summit brings together medical professionals involved with Myeloma in NZ to share and to learn from one another and from the international speakers who join the meeting. This year...Continue Reading
MEDIA RELEASE DOCTOR CALLS ON MINISTER LITTLE TO RELEASE ‘BURIED’ INDEPENDENT REPORT ON PHARMAC The final report of the Independent Pharmac Review Panel has been sitting with Health Minister Andrew Little since February, with no reason offered for why it has not been released, says Myeloma NZ Chief Executive Dr Ken Romeril. “Given the damning...Continue Reading
Congratulations on your very well-deserved appointment to The New Zealand Order of Merit for your services to Haematology! Dr Ken Romeril is a consultant physician/haematologist. Dr Ken Romeril (Ken) founded the charitable trust Myeloma New Zealand, of which he has been CEO since 2016, continuing in this role following retirement from clinical practice. He is the...Continue Reading
As we continue to understand more about the biology of multiple myeloma (MM) and the number of treatment options for patients with MM continues to expand, keeping track of the current standard of care practices and emerging new treatment strategies has become even more challenging. In this commentary, we will summarize our thoughts on how...Continue Reading
The Cancer Control Agency’s analysis of the gap between Australia and New Zealand in funding 18 selected medicines with substantial clinical benefit is a welcome way of drawing attention to the plight of NZ cancer patients desperate for treatments that are funded across the Tasman, but not here, says Myeloma NZ Chief Executive Dr Ken...Continue Reading
The Access Criteria for the oral antiviral COVID-19 treatments, nirmatrelvir with ritonavir (Paxlovid) and molnupiravir (Lagevrio) has been announced. These Access Criteria have been developed with the advice of clinical expert advisors. Supply of the oral treatments will be arriving throughout 2022 and the criteria have been designed to help support prescribers to target available...Continue Reading
After New Year’s Honours for his work, he now fears could die without seeing a single new myeloma-fighting drug added to those funded by Pharmac, the government drug-buying agency he labels as “glacial”. Read more here: Honoured haematologist and HIV pioneer fears he won’t see action from ‘glacial’ Pharmac in his lifetime | Stuff.co.nzContinue Reading
